Examination of the Postprandial Bone Remodeling in Persons With Reduced GIP-Receptor Activity

Examination of the Postprandial Bone Remodeling in Persons With Reduced Activity of the Receptor for the Enteric Hormone Glucose-dependent Insulinotropic Polypeptide

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02518737

Enrollment

Registered

2015-08-10

Start date

2015-09-30

Completion date

2016-06-30

Last updated

2016-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone Remodeling

Keywords

Glucose-dependent Insulinotropic Polypeptide, Receptor Deficiency

Brief summary

The bone tissue of the human adult body is in a constant process of break-down (resorption) and rebuilding (formation), a process called bone remodeling. The extent to which bone remodeling happens varies during the day, especially a decrease in the bone resorption is observed after eating. The overall purpose of this study is to examine the possible role of the hormone Glucose-dependent Insulinotropic Polypeptide (GIP) in Bone Remodeling. GIP is released from cells in the gut after eating, and previous studies have shown an effect of GIP on bone tissue. In addition, it has been observed that the risk of bone fracture is 60% higher in women with a mutation in the GIP receptor, when compared to women with a normal functioning GIP receptor. In the present study humans with a mutation in their GIP receptor is compared to humans with a normal functioning GIP receptor. The study population will be examined during a meal stimulation test, where blood will be sampled regularly. The blood samples will be examined for markers of bone resorption among other markers of bone remodeling, GIP and other gut hormones. The hypothesis for the present study is that GIP secreted after meal ingestion inhibits bone resorption. Thus it is expected that the decrease in resorption is less pronounced in the humans carrying the GIP-receptor mutation, compared to humans with a normal functioning GIP receptor.

Interventions

OTHERMeal Test

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Verified mutation (Glu354Gln) of the GIP-receptor

Exclusion criteria

* Type 2 diabetes * Pregnancy * Previous long-lasting treatment with steroids * On-going steroid treatment (with the exception of inhalation-steroids) * Osteoporosis

Design outcomes

Primary

Measure	Time frame	Description
CTx	7, 15, 30, 45, 60, 90, 120, 150, 180, 240 minutes after intake of the meal test.	CTx is a biomarker of bone resorption.

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026